Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
A woman died during scenes of panic at a Kenyan university after police carried out a terror drill without the students being told first.
The Prince of Wales said world companies 'pay no attention' to the damage their supply chains cause to forests.
Investigators say a faulty rudder system and the pilots' responses contributed to an AirAsia jet crash last year which killed 162 people.